SEC Tracker
Get the app
RMTI · XBRL financial data

Rockwell Medical financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RMTI's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Cost of goods and services sold21,56919,223*19,61221,28222,07721,034*15,87213,56813,65514,468*14,43914,537
Gross profit2,202—3,0644,5506,239—3,0422,5032,272—2,8973,243
Research and development494168*18001*0000*—40
General and administrative2,8892,708*3,7763,4493,5773,306*3,6913,2803,3253,736*3,8103,687
Operating income (loss)(1,737)(547)*(1,324)5151,936(519)*(1,360)(1,349)(1,584)(398)*(1,480)(1,061)
Interest income—year only——————————
Interest expense4111,108*431232302289*277276285286*282281
Other income (expense)(135)(965)*(407)(172)(272)(237)*(155)(143)(169)(156)*(125)(111)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(1,872)(1,512)*(1,731)3431,664(756)*(1,515)(1,492)(1,753)(554)*(1,605)(1,172)
Earnings per share, basic‡ USD per share(0.01)—(0.06)0.010.05(0.02)*(0.04)(0.05)(0.05)(0.01)*(0.04)(0.34)
Earnings per share, diluted‡ USD per share(0.01)—(0.06)0.010.04(0.02)*(0.04)(0.05)(0.05)(0.01)*(0.04)—
Weighted average shares, basic‡ thousands of shares302,430—29,32730,45231,55232,878*34,10834,31136,02539,394*39,4183,959
Weighted average shares, diluted‡ thousands of shares302,430—29,32732,03432,42030,445*34,10834,31136,02539,394*39,4183,959
  • † Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/10 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (RMTI's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Cash and cash equivalents7,7598,9836,64211,86312,33815,66211,39112,48213,61010,7119,60910,519
Marketable securities3,9711,9521,97705,9345,940———14,286——
Accounts receivable9,36110,90111,09410,8408,8868,2919,6708,0848,3288,1438,8258,305
Inventory5,4865,8716,0735,8835,8885,7785,0454,1603,9643,4243,0552,817
Prepaid and other current assets1,5961,0639101,1671,1711,3599889431,5151,5991,173441
Total current assets28,17328,77026,69629,75334,21737,03033,03431,60937,51438,16336,94336,360
Property and equipment, net6,7716,4026,1346,0095,7955,7855,3945,1294,9524,6294,3284,622
Right-of-use asset3,0952,7133,8843,5153,5983,2152,8173,4082,9912,5694,6084,240
Goodwill921921921921921921921921921921921920
Total assets52,60652,17350,72353,02857,08459,20853,96152,62557,48657,14557,42356,526
Accounts payable3,9294,5164,9193,3472,6072,8691,9251,5021,5231,9993,4463,179
Accrued liabilities6,7087,1495,2536,1686,2906,2754,5784,0963,8654,3373,1603,973
Current portion of long-term debt5,6310———————07071,768
Total current liabilities21,40816,63714,94914,89114,17814,09111,20510,9469,5829,5809,86811,174
Long-term debt3,3318,2938,2658,2958,3838,4728,5598,6488,7378,8268,2077,235
Lease liability, non-current1,6761,4332,5042,1422,0981,6991,4012,0081,7241,4543,3012,933
Total liabilities31,08830,88230,08029,53027,94926,62222,43922,21620,46620,16421,56621,441
Accumulated deficit(395,686)(397,198)(398,929)(398,586)(396,922)(397,678)(399,193)(400,685)(402,438)(402,992)(404,597)(405,769)
Total stockholders' equity21,51821,29120,64323,49829,13532,58631,52230,40937,02036,98135,85735,085
Total liabilities and equity52,60652,17350,72353,02857,08459,20853,96152,62557,48657,14557,42356,526
Common shares outstanding (cover page)‡ thousands of shares313,07329,33530,31631,03032,31934,05734,17534,43039,40539,40539,4704,030
  • † Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/10 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (RMTI's year ends in late December)

In thousands of dollarsSep 30, 2023†Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Net income (loss)(1,872)(1,512)*(1,731)3431,664(756)*(1,515)(1,492)(1,753)(554)*(1,605)(1,172)
Stock-based compensation212*218*251338*321*382*445382*532*457*479403*
Depreciation and amortization564*550*545549*543*543*539563*544*546*511492*
Net cash from operating activities(3,753)*(43)*(2,380)1,442*4,275*865*(3,487)1,844*(1,307)*2,291*(167)2,080*
Net cash from investing activities(10,291)*2,008*(139)1,717*(6,112)*(332)*(1)(103)*(4,309)*(4,131)*(122)(487)*
Proceeds from issuing common stock13,763*1,098*5602,203*3,630*3,788*00*7,816*0*——
Net cash from financing activities12,845*(742)*1782,065*2,313*2,792*(783)(650)*6,744*(1,059)*(813)(683)*
Net change in cash(1,200)*1,224*(2,341)5,221*475*3,324*(4,271)1,091*1,128*(2,899)*(1,102)910*
  • † Share count changed about 1/11 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1/10 in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Rockwell Medical10,519not reported2,080*4.0M— 10-QJun 30, 2026
Champions Oncology4,35815,232(492)13.9M8.0 quarters 10-QJul 31, 2026
OnKure Therapeutics166,502not reported(10,354)*40.5M17.0 quarters 10-QJun 30, 2026
Cumberland Pharmaceuticals3,862166169*15.0M— 10-QJun 30, 2026
ProMIS Neurosciences53,429not reported(10,385)*9.0M5.1 quarters 10-QJun 30, 2026
Tempest Therapeutics779not reported(2,779)*16.0M0.3 quarters 10-QJun 30, 2026
Provectus Biopharmaceuticals1,157not reported(358)*420.3M3.2 quarters 10-QJun 30, 2026
Outlook Therapeutics11,242not reported(21,011)*243.4M0.5 quarters 10-QJun 30, 2026
Yarrow Bioscience22,92597(1,992)*2.7M11.5 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.